Fomivirsen (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fomivirsen" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2web.archive.org

1^st place

1^st place

2^nd place

2^nd place

low place

low place

234^th place

397^th place

68^th place

117^th place

low place

low place

1semanticscholar.org

11^th place

8^th place

ajmc.com

Bubela T, McCabe C (July 2014). "Value-engineered translation: developing biotherapeutics that align with health-system needs". The American Journal of Managed Care. 20 (10 Spec No): E3. PMID 25830190. Archived from the original on 2017-09-29. Retrieved 2017-01-02.

baystreet.ca

"Initiating Coverage: Rexahn Pharmaceuticals (RNN)" (PDF). LifeSci Capital. May 23, 2016.

doi.org

Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)". Antimicrobial Agents and Chemotherapy. 42 (4): 971–973. doi:10.1128/AAC.42.4.971. PMC 105584. PMID 9559825.
Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–1193. doi:10.1126/science.276.5316.1192. PMID 9182327. S2CID 6983051.

europa.eu

ema.europa.eu

"Public Statement on Vitravene (fomiversen): Withdrawal of the Marketing Authorization in the European Union" (PDF). EMA. August 6, 2002. Archived from the original (PDF) on May 23, 2018. Retrieved January 2, 2017.

nature.com

blogs.nature.com

Jiang K (February 19, 2013). "Biotech comes to its 'antisenses' after hard-won drug approval : Spoonful of Medicine". Nature Medicine: Spoonful of Medicine Blog.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bubela T, McCabe C (July 2014). "Value-engineered translation: developing biotherapeutics that align with health-system needs". The American Journal of Managed Care. 20 (10 Spec No): E3. PMID 25830190. Archived from the original on 2017-09-29. Retrieved 2017-01-02.
Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)". Antimicrobial Agents and Chemotherapy. 42 (4): 971–973. doi:10.1128/AAC.42.4.971. PMC 105584. PMID 9559825.
Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–1193. doi:10.1126/science.276.5316.1192. PMID 9182327. S2CID 6983051.

ncbi.nlm.nih.gov

Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)". Antimicrobial Agents and Chemotherapy. 42 (4): 971–973. doi:10.1128/AAC.42.4.971. PMC 105584. PMID 9559825.

semanticscholar.org

api.semanticscholar.org

Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–1193. doi:10.1126/science.276.5316.1192. PMID 9182327. S2CID 6983051.

web.archive.org

Bubela T, McCabe C (July 2014). "Value-engineered translation: developing biotherapeutics that align with health-system needs". The American Journal of Managed Care. 20 (10 Spec No): E3. PMID 25830190. Archived from the original on 2017-09-29. Retrieved 2017-01-02.
"Public Statement on Vitravene (fomiversen): Withdrawal of the Marketing Authorization in the European Union" (PDF). EMA. August 6, 2002. Archived from the original (PDF) on May 23, 2018. Retrieved January 2, 2017.